News

Cutaneous Lupus Erythematosus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In April 2025, Pfizer organized a study is to learn about the effects, safety and how PF-06823859 is processed in adults with ...
Yahoo Finance7d
Specialists Set Sights on CLE Pipeline as Unmet Needs Persist and Candidate Pool Expands, According to Spherix Global Insights
Biogen’s litifilimab, which targets BDCA2 on plasmacytoid dendritic cells, has drawn particular attention for its monthly dosing, steroid-sparing potential, and novel mechanism of action.